Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the
treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB,
IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.